Condition: Ovarian Cancer · Sponsor: National Cancer Institute, Naples
MITO 35b is designed as randomized, open label, phase III trial that aims to assess the efficacy of olaparib maintenance beyond progression compered to standard platinum-based chemotherapy after secondary cytoreductive surgery. The target population of this study are ovarian cancer patients who experience a disease recurrence or progression to a first line maintenance therapy with PARPi; at progression patients must have received a secondary cytoreduction according to clinical practice.
This description comes directly from the study's public registry record.
Clorinda Schettino, MD · 003908159031791 · c.schettino@istitutotumori.na.it
Sandro Pignata, MD · 00390815903409 · s.pignata@istitutotumori.na.it
Always discuss trial participation with your own doctor first.
| IRCCS Istituto Nazionale Tumori di Napoli | Naples, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05255471